Research Article

Danggui Buxue Decoction Ameliorates Idiopathic Pulmonary Fibrosis through MicroRNA and Messenger RNA Regulatory Network

Huizhe Zhang,1,2 Xue Wang,1 Yanchen Shi,1 Mengying Liu,3 Qingqing Xia,4 Weilong Jiang,4 and Yufeng Zhang4

1Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China
2Department of Respiratory Medicine, Yancheng Hospital of Traditional Chinese Medicine, Yancheng Hospital Affiliated to Nanjing University of Chinese Medicine, Yancheng, Jiangsu 224005, China
3Department of Pulmonary and Critical Care Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu 210008, China
4Department of Pulmonary and Critical Care Medicine, Jiangyin Hospital of Traditional Chinese Medicine, Jiangyin Hospital Affiliated to Nanjing University of Chinese Medicine, Jiangyin, Jiangsu 214400, China

Correspondence should be addressed to Yufeng Zhang; yufengzhang@njucm.edu.cn

Received 13 January 2022; Revised 25 March 2022; Accepted 5 April 2022; Published 26 April 2022

Academic Editor: Jun Jiang

Copyright © 2022 Huizhe Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To develop a putative microRNA (miRNA) and messenger RNA (mRNA) regulatory network of Danggui Buxue decoction’s (DGBXD) amelioration of idiopathic pulmonary fibrosis (IPF). Methods. The Gene Expression Omnibus (GEO) database was used to identify differentially expressed miRNAs (DE-miRNAs) and differentially expressed mRNAs (DE-mRNAs). Using miRNet, the predicted target genes of identified DE-miRNAs were estimated, and then the target genes of DE-miRNAs in IPF were comprehensively examined. The Enrichr database was used to conduct functional enrichment and pathway enrichment. Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) was employed to obtain the target genes of DGBXD as well as active compounds. A putative miRNA-mRNA regulatory network of DGBXD acting on IPF was developed by intersecting the target genes of DGBXD with the DE-miRNA target genes in IPF. Results. Fourteen upmodulated DE-miRNAs and six downmodulated DE-miRNAs were screened. The downstream target genes of upmodulated and downmodulated DE-miRNAs were predicted. Subsequently, 1160 upmodulated DE-miRNAs and 1427 downmodulated DE-miRNAs were identified. Then, target genes of DE-miRNAs comprising 49 downmodulated and 53 upmodulated target genes were further screened to perform functional enrichment and pathway enrichment analyses. Subsequently, 196 target genes of DGBXD were obtained from TCMSP, with six downregulated target genes and six upregulated target genes of DGBXD acting on IPF being identified. A promising miRNA-mRNA regulatory network of DGBXD acting on IPF was developed in this study. Moreover, mir-493 together with its target gene Olr1 and mir-338 together with Hif1a were further validated by qRT-PCR. Conclusion. This study proposed detailed possible processes of miRNA-mRNA modulatory axis in IPF and constructed a prospective IPF-related miRNA-mRNA modulatory network with the aim of alleviating IPF with DGBXD.

1. Introduction

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung condition whose characteristics include pulmonary fibrosis. The etiology of IPF remains unknown, with its pathological manifestation being usual interstitial pneumonia (UIP) [1]. IPF is more common in the elderly, but it is a rare disease with an estimated incidence of approximately 2.8–9.3 per 100,000 people in Europe and North America [2–4]. However, in China, epidemiological data...
about this condition are scarce, although its incidence has significantly increased in recent years [5]. IPF cannot be cured, so the main goals of the current treatment are to delay disease progression, improve quality of life, and prolong patient survival [6]. Limited drug options are available for IPF, with pirfenidone and nintedanib having obvious curative effects, while traditional Chinese medicine (TCM) can play an integral role in managing IPF [7–10]. Nonetheless, the prognosis of patients with IPF remains dismal, with median survival duration of approximately 2–3 years from the initial diagnosis [11]. There is thus a crucial need to develop a successful treatment for IPF.

MicroRNAs (miRNAs) are endogenous, double-stranded small RNA molecules ranging in length between 20 and 24 nucleotides that do not encode proteins [12]. MiRNAs play an integral role in silencing RNA and post-transcriptionally modulating the expression of genes by interacting with messenger RNA (mRNA) via the base pairs of intramolecular complementary sequences [13]. Studies have reported that a single miRNA can regulate numerous genes, while many miRNAs can also coregulate a single gene. Therefore, miRNAs are involved in myriad cellular activities, such as cell differentiation, apoptosis, proliferation, migration, and energy metabolism [14]. Furthermore, miRNAs play significant roles in organ fibrosis, particularly in IPF, potentially being correlated with disease pathogenesis [15–19].

Studies have demonstrated that TCM can modulate miRNA-mRNA networks in the treatment of different diseases [20–22]. However, to the best of our knowledge, no evidence has been reported on the use of TCM for treating IPF through regulating the miRNA-mRNA network. Recently, in a study conducted by the authors of this paper, a putative IPF-related miRNA-mRNA modulatory network was developed, which could aid in the discovery of new miRNA-mRNA axes of IPF [23]. This can also promote further studies on TCM acting on IPF-related miRNA-mRNA regulatory networks.

Danggui Buxue decoction (DGBXD), which is an ancient classical formula among hundreds of thousands of TCM formulae, has been clinically used in China for over 800 years. The two herbs contained in DGBXD are Radix Astragali (RA; Huangqi in Chinese) and Radix Angelicae Sinensis (RAS; Danggui in Chinese) [24]. Recently, a series of studies on the use of DGBXD for treating IPF were conducted. The obtained results confirmed the effectiveness and safety of RA and RAS in IPF patients [25] and clarified the multipathway, multitarget, and multicomponent mechanisms by which RA and RAS act in the treatment of IPF [26, 27]. Therefore, DGBXD can effectively treat IPF by targeting multiple genes. Building on the previous reports on DGBXD- and miRNA-related studies [28, 29] and the miRNA-mRNA regulatory network that we developed earlier, this study further investigates whether DGBXD alleviates IPF by regulating the miRNA-mRNA modulatory network, which can facilitate further research of the relevant miRNA-mRNA pairs experimentally verified and the material basis by which DGBXD acts on IPF through the miRNA-mRNA modulatory network.

In this research, differentially expressed miRNAs (DE-miRNAs) between tissues of patients with IPF and tissues of healthy controls were screened for the first time using miRNA datasets and downstream target genes of the DE-miRNAs and were predicted using a network database. In addition, differentially expressed mRNAs (DE-mRNAs) between IPF and normal tissues were acquired with the aid of an IPF mRNA dataset. Moreover, target genes of DE-miRNAs in IPF were identified to conduct functional enrichment based on Gene Ontology (GO) and pathway enrichment based on the Kyoto Encyclopedia of Genes and Genomes (KEGG). Subsequently, target genes of DGBXD, as well as active compounds, were discovered. After the active target genes of DGBXD intersected with the DE-miRNA target genes in IPF, the target genes of DGBXD acting on IPF were also determined. Ultimately, a putative miRNA-mRNA regulatory network associated with the action of DGBXD on IPF was identified. The experimental verification of relevant miRNA-mRNA pairs was performed, which should facilitate further research.

2. Materials and Methods

2.1. Searching and Screening of Microarray Datasets. A search for datasets focusing on the miRNAs and mRNAs related to IPF was performed in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/gds/). Taking miRNA expression as an example, the retrieval strategy used in this study was as follows: [“microRNAs” (MeSH Terms) OR “microRNA” (All Fields)] AND “idiopathic pulmonary fibrosis” (All Fields). Datasets derived from IPF clinical patients and containing IPF-related and normal samples were screened for inclusion in this study.

2.2. Identification of DE-miRNAs. We employed the GEO2R online tool (https://www.ncbi.nlm.nih.gov/geo/geo2r/) to directly detect DE-miRNAs between IPF and normal samples in the screened miRNA datasets [30, 31]. Differentially expressed miRNAs were identified by GEO2R by comparing the IPF group with the normal group, setting |log2FoldChange (FC)| > 1 and adjusted (adj) p value < 0.05 as the cut-off values.

2.3. Predicting Downstream Target Genes of DE-miRNAs. The miRNet (https://www.mirnet.ca/) platform, which is an integrative platform integrating miRNAs, functions, and targets, was used for the purpose of estimating the downstream target genes of DE-miRNAs [32–34]. The DE-miRNAs that were downmodulated and upmodulated were entered into the web platform, while the data of target genes of downmodulated and upmodulated DE-miRNAs were downloaded.

2.4. Identification of DE-mRNA and DE-miRNA Target Genes in IPF. The screened IPF-related mRNA datasets were analyzed to enhance the validity of our additional analysis of
the target genes of DE-miRNAs that had been screened. Series matrix files were downloaded from the GEO database. Setting \(\log_{2}FC > 1\) and ad\(\ p\) value < 0.05 as the cut-off values, DE-miRNAs in IPF were discovered with the aid of the RGUI and limma packages [35].

Then, an intersection analysis of DE-miRNAs and predicted target genes of DE-miRNAs was performed for the purpose of identifying the target genes of DE-miRNAs in IPF.

2.5. GO Functional Enrichment and KEGG Pathway Enrichment Analyses. The Enrichr database, a reliable online tool for Gene Set Enrichment Analysis (https://amp.pharm.mssm.edu/Enrichr/), was used to conduct analyses of GO functional enrichment and KEGG pathway enrichment for the target genes [36, 37]. Subsequently, we entered target genes into the web platform for the purpose of obtaining data regarding GO functional enrichment and KEGG pathway enrichment. GO functional analysis comprises three classifications: cellular component (CC), molecular function (MF), and biological process (BP). We set a \(p\) value of <0.05 to indicate a statistically significant difference.

2.6. Identification of Active Target Genes of DGBXD and Active Compounds. We used the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP; https://old.tcmsp-e.com/tcmsp.php) to obtain the chemical compounds and their corresponding target genes in DGBXD (RA and RAS) [38]. Drug-likeness (DL) \(\geq 0.18\) and oral bioavailability (OB) \(\geq 30\)% were established as thresholds to identify the active compounds, with reference to previous studies [26, 39]. All human gene symbols were corrected to their official gene symbols with the aid of UniProt Knowledgebase (https://www.uniprot.org/) [40, 41].

2.7. Determination of Target Genes of DGBXD Acting on IPF. The target genes of the active compounds of DGBXD that overlapped with the target genes of DE-miRNAs in IPF were selected as target genes of DGBXD acting on IPF. According to their corresponding miRNAs, a potential miRNA-mRNA regulatory network of DGBXD acting on IPF was established.

2.8. Animal Experiments. We procured C57BL/6 wild-type mice from the Animal Core Facility of Nanjing Medical University (Nanjing Medical University, Nanjing, China). A total of 30 male mice ranging in age from 6 to 8 weeks, weighing 18 to 22 g, were kept in a controlled setting and fed conventional rodent chow, as well as being provided with free access to water. The mice were classified into three groups at random (\(n = 10\) for each group): bleomycin group (Model), control group (Control), and bleomycin + DGBXD group (Treatment). For the purpose of inducing fibrosis, the mice in the model and treatment groups were administered \(50 \, \mu\)l of bleomycin (5 mg/kg) (Nippon Kayaku Co., Ltd., Tokyo, Japan), while those in the control group received normal saline (NS) via intratracheal injection, through an endotracheal quantitative microsprayer aerosolizer (Shanghai Yuyan Instruments Co., Ltd., Shanghai, China) [42]. The day after modeling, the control and model groups were intragastrically administered NS, whereas the animals in the treatment group were administered DGBXD once a day for 3 weeks. DGBXD granules were purchased from Jiangyin Tianjiang Pharmaceutical Co., Ltd. (Jiangyin, China) (Table S1). RA and RAS were dissolved with NS at a \(5 : 1\) ratio. Dosages of DGBXD were set based on their clinical dosages and previous studies [43–45]. The following dosages were used: 4.68 mg/g; RA: 3.90 mg/g, and RAS: 0.78 mg/g (crude drug), calculated according to a body weight of 70 kg for adults using 30 g of RA and 6 g of RAS. Mice were anesthetized and sacrificed on day 21 for further experiments. All of the procedures were approved by the Ethics Committee for Animal Experiments of Nanjing University of Chinese Medicine (A211201).

2.9. Histopathological Analysis. On day 21 following the initial therapy, the mice were euthanized and their lungs were extracted for further examination. A 10% formaldehyde solution was used to fix the lung tissue samples, followed by embedding in paraffin and slicing into 5-\(\mu\)m sections. We applied hematoxylin-eosin (HE) and Masson staining to determine whether the lungs had been injured or changed in terms of their morphological appearance. The Szapiel score and Ashcroft score were used to semiquantitatively assess the histopathological changes in a blinded manner [46, 47]. The scoring standards are shown in Tables S2 and S3. The scores were assessed separately by two of the authors.

2.10. RNA Extraction, Reverse Transcription, and Real-Time Quantitative Polymerase Chain Reaction (qRT-PCR). RNAiso Plus (Takara) was used for extracting total RNA from the lung tissues of the mice. PrimeScript™ RT Master Mix (Takara) was employed to reverse-transcribe the isolated RNA into complementary DNA (cDNA). Takara’s TB Green® Premix Ex Taq™ II (Takara) was applied to quantify the levels of mRNA expression, with GAPDH expression used as an internal reference. The qRT-PCR was carried out using primers with the following sequences: Olr1: forward: 5’-CAA TTT CCC ATA CCA CCT CCC-3’, reverse: 5’-AGT TCC ATT CTC CCA TAG CCA-3’; Hif1a: forward: 5’-ATT TTG GCA GCG ATG ACA CAG-3’, reverse: 5’-CTT TGG AGT TTC CGA TGA AGG TA-3’, and GAPDH: forward: 5’-GAA CGG GAA GCT CAC TGG-3’, reverse: 5’-GCC TGC TTC ACC ACC TTC T-3’. Greenzhou RiboBio Co., Ltd. (Guangzhou, China), supplied the mir-493 and mir-338 primers, and U6 small nuclear RNA (snRNA) as an internal control. In accordance with the manufacturer’s instructions, miRNA qRT-PCR was conducted using the Bulge-loop™ miRNA qRT-PCR Starter Kit (Guangzhou RiboBio Co., Ltd.) [48]. Quantification of data was performed by the comparative 2\(-\Delta\Delta Ct\) method.

2.11. Statistical Analysis. Some statistical analyses were carried out directly using the bioinformatic tools available with the aid of the websites indicated above. Only miRNAs
or mRNAs with $|\log_{2}FC| > 1$ and adj $p$ value $< 0.05$ were deemed to have statistical significance when differential expression analysis was performed, whether RGui or GEO2R was used. A $p$ value $< 0.05$ was considered to indicate statistical significance in the GO functional enrichment and KEGG pathway enrichment analyses. GraphPad Prism (version: 8.0.2) and IBM SPSS Statistics (version: 25.0) were employed to conduct the qRT-PCR analyses in this study. One-way ANOVA was performed to conduct statistical analysis on the statistics and data assessment. A $p$ value $< 0.05$ was considered to indicate statistical significance.

### 3. Results

#### 3.1. Screened miRNA Datasets and Identified DE-miRNAs.
A total of three microarray datasets (GSE13316, GSE27430, and GSE75647) that met the inclusion criteria mentioned above were selected for subsequent analysis. These microarray datasets contained data on IPF and normal samples. The GSE13316 dataset was based on the platform GPL6955, GSE27430 was based on the platform GPL8227, and GSE75647 was based on the platform GPL21199. The three datasets were chosen to filter DE-miRNAs between IPF and normal samples. miRNAs were discovered directly using GEO2R by designated groups, each of which contained the miRNA expression data. Adj $p$ value $< 0.05$ and $|\log_{2}FC| > 1$ were set as the cut-off values for detecting DE-miRNAs. Figure 1 shows a volcano plot of the DE-miRNAs.

After removing duplicates, 14 upregulated DE-miRNAs in IPF (miR-127-3p, miR-654-3p, miR-409-3p, miR-487b, miR-495, miR-432, miR-369-5p, miR-410, miR-299-5p, miR-382, miR-409-5p, miR-493, miR-154, miR-31) and six downregulated DE-miRNAs in IPF (miR-30b, miR-326, miR-203, miR-338-3p, miR-375, miR-184) were detected.

#### 3.2. Predicted Downstream Target Genes of DE-miRNAs.
When predicting the downstream target genes of DE-miRNAs, we employed the miRNet database because miRNAs have the greatest potential to exert their biological effects by specifically targeting the 3′ untranslated region of mRNAs. The predicted downstream target genes of the upregulated DE-miRNAs numbered 1285 genes (Table S4), whereas those of the downregulated DE-miRNAs numbered 1411 genes (Table S5). We established a network of the upmodulated DE-miRNA-target genes as depicted in Figure 2(a), and one of the downmodulated DE-miRNA-target genes as shown in Figure 2(b).

#### 3.3. Searched mRNA Dataset and Identified DE-mRNAs.
The GEO database was searched for the purpose of obtaining datasets containing information about mRNA expression.

---

**Table 1: Target genes of upmodulated DE-miRNAs in IPF.**

| Target genes | Upregulated DE-miRNAs | Target genes | Upregulated DE-miRNAs |
|--------------|------------------------|--------------|------------------------|
| ZNF331       | miR-31-5p              | CABP4        | miR-410-3p             |
| CASKIN2      | miR-31-5p              | HHIP         | miR-410-3p             |
| SPRY4        | miR-31-5p              | RAB11FIP1    | miR-410-3p             |
| FOXD4L1      | miR-31-5p              | CADM2        | miR-410-3p             |
| MAPK4        | miR-127-3p             | FOS          | miR-493-5p             |
| PER3         | miR-154-5p             | OLR1         | miR-493-5p             |
| VSIG2        | zmiR-154-5p            | CITED2       | miR-493-5p             |
| PTGDR        | miR-382-5p             | FREM2        | miR-493-5p             |
| FAM105 A     | miR-382-5p             | ID4          | miR-432-5p             |
| SYT13        | miR-382-5p             | KCNK16       | miR-432-5p             |
| FABP4        | miR-369-5p             | MOGAT1       | miR-432-5p             |
| GAB1         | miR-369-5p             | SEC14L4      | miR-432-5p             |
| IFNG         | miR-409-3p             | PER2         | miR-495-3p             |
| EFR3B        | miR-409-3p             | DLC1         | miR-495-3p             |
| SLC26A7      | miR-409-3p             | GALNT8       | miR-495-3p             |
| CCDC38       | miR-409-3p             | CCDC141      | miR-495-3p             |
| HCAR2        | miR-409-3p             | LIFR         | miR-493-3p             |
| KLF6         | miR-410-3p             | MAP2         | miR-493-3p             |
| CD55         | miR-410-3p             | FZD4         | miR-493-3p             |
| DUSP8        | miR-410-3p             | GRM3         | miR-487b-3p            |
| VEGFA        | miR-410-3p             | ADRB1        | miR-654-3p             |
| FZD5         | miR-410-3p             | PKIA         | miR-654-3p             |
| ARHGAP29     | miR-410-3p             | CDK5L2       | miR-654-3p             |
| SLC25A27     | miR-410-3p             | PRSS21       | miR-654-3p             |
| HEY1         | miR-410-3p             |              |                        |

DE-miRNA: differentially expressed microRNA; IPF: idiopathic pulmonary fibrosis.

---

or mRNAs with $|\log_{2}FC| > 1$ and adj $p$ value $< 0.05$ were deemed to have statistical significance when differential expression analysis was performed, whether RGui or GEO2R was used. A $p$ value $< 0.05$ was considered to indicate statistical significance in the GO functional enrichment and KEGG pathway enrichment analyses. GraphPad Prism (version: 8.0.2) and IBM SPSS Statistics (version: 25.0) were employed to conduct the qRT-PCR analyses in this study. One-way ANOVA was performed to conduct statistical analysis on the statistics and data assessment. A $p$ value $< 0.05$ was considered to indicate statistical significance.
Datasets based on IPF clinical patients containing data on IPF and normal samples were also included. Finally, one dataset (GSE92592) was chosen for further investigation. The platform GPL11154 served as the foundation for GSE92592.

This dataset was selected for the purpose of determining the DE-miRNAs between IPF and normal samples. A series of matrix files was obtained from the GEO database. Applying RGui and limma package to the analysis of variance, differentially expressed miRNAs were identified. |log2FC| > 1 and |adj p value| < 0.05 were established as the cut-off values for detecting DE-miRNAs. Finally, we identified 1160 upmodulated DE-miRNAs in IPF (Table S6) and 1427 downmodulated ones (Table S7). Figure 3 shows a volcano plot of the DE-miRNAs.

3.4. Identified DE-miRNA Target Genes in IPF. There is typically a negative correlation between the level of an miRNA and the level of mRNA expression of its target gene. A combined assessment of 1427 downmodulated DE-miRNAs and 1285 predicted target genes of upmodulated DE-miRNAs was carried out in this study. Subsequently, 49 target genes of the upmodulated DE-miRNAs were discovered (Figure 4(a), Table 1). A combined evaluation of 1160 upmodulated DE-miRNAs and 1411 predicted target genes of downmodulated DE-miRNAs was also performed. Subsequently, 53 target genes of downregulated DE-miRNAs were discovered (Figure 4(b), Table 2).

3.5. GO Functional Enrichment and KEGG Pathway Enrichment. The identified DE-miRNA target genes were subjected to GO functional enrichment and KEGG pathway enrichment analyses, both of which were accomplished using the Enrichr database.

The findings from GO CC analysis demonstrated that the target genes of the upregulated DE-miRNAs were particularly associated with pathways in cancer, breast cancer, basal cell carcinoma, proteoglycans in cancer, signaling pathways regulating pluripotency of stem cells, rheumatoid arthritis, cyclic adenosine monophosphate (cAMP), interleukin 17 signaling pathway, circadian entrainment, and circadian rhythm, among others (Figure 5(f)). Meanwhile, the findings from GO MF analysis demonstrated that the target genes of the downregulated DE-miRNAs were particularly associated with transcription corepressor binding, PDZ domain binding, transcription cofactor binding, G-protein-coupled receptor activity, and Wnt-activated receptor activity, among others (Figure 5(b)). Finally, the findings from GO BP analysis illustrated that the target genes for the upmodulated DE-miRNAs were strongly associated with negative regulation of DNA binding, regulation of adiponectin secretion, heart morphogenesis, vascular endothelial growth factor (VEGF) signaling pathway, and positive regulation of cell migration by the VEGF signaling pathway, among others (Figure 5(c)).

The results obtained from GO CC analysis showed that the target genes of the downregulated DE-miRNAs were particularly associated with platelet alpha granule, platelet alpha granule membrane, nuclear chromosome, filopodium, and dendrite, among others (Figure 5(d)). Meanwhile, the findings from GO MF analysis demonstrated that the target genes of the downregulated DE-miRNAs were particularly linked with transcription factor activity RNA polymerase II core promoter proximal region sequence-specific binding, transcriptional activator activity RNA polymerase II core promoter proximal region sequence-specific binding, VEGF receptor 2 binding, transcriptional activator activity RNA polymerase II transcription regulatory region sequence-specific binding, and metalloendopeptidase activity, among others (Figure 5(e)). Finally, GO BP analysis showed that the target genes of the downregulated DE-miRNAs demonstrated particular links with extracellular matrix organization, positive regulation of gene expression, positive regulation of nucleic acid-templated transcription, negative regulation of neuron apoptotic process, and cellular response to cytokine stimulus, among others (Figure 5(f)).

KEGG pathway enrichment analysis was also conducted on the genes that were targeted by DE-miRNAs. The results showed that the target genes of the upmodulated DE-miRNAs were particularly associated with pathways in cancer, breast cancer, basal cell carcinoma, proteoglycans in cancer, signaling pathways regulating pluripotency of stem cells, rheumatoid arthritis, cyclic adenosine monophosphate (cAMP), interleukin 17 signaling pathway, circadian entrainment, and circadian rhythm, among others.
Figure 2: Predicted downstream target genes of DE-miRNAs. (a) miRNet was used for establishing a network of upmodulated DE-miRNAs and their target genes. Blue rectangles represent 15 upmodulated DE-miRNAs (miR-31 is represented in both miR-31-3p and miR-31-5p in miRNet); brown dots represent target genes. (b) miRNet was used for establishing a network of downmodulated DE-miRNAs and their target genes. Blue rectangles represent six downmodulated DE-miRNAs; brown dots represent target genes.
3.6. Identified Active Compounds and Target Genes of DGBXD.

This study identified 87 compounds in RA and 125 compounds in RAS, using TCMSP. Among these, 22 active compounds in DGBXD were predicted (20 in RA and 2 in RAS) (Table 3) upon setting the criteria of DL ≥ 0.18 and OB ≥ 30%. TCMSP was also used for determining the target genes for each of these 22 compounds (Table S6). The gene symbols were filtered using UniProt Knowledgebase, with the format "Homo sapiens" being used to identify them. Finally, we acquired a total of 196 active target genes of DGBXD (Table 4).

3.7. Identified Target Genes of DGBXD Acting on IPF.

We determined those genes among the 196 active target genes of DGBXD that overlapped with the 49 target genes of upmodulated DE-miRNAs and the 53 target genes of downmodulated DE-miRNAs. This led to identification of the target genes through which DGBXD acts on IPF, namely, six downmodulated genes (Figure 7(a)) and six upmodulated ones (Figure 7(b)).

3.8. Identified Putative miRNA-mRNA Regulatory Network of DGBXD Acting on IPF.

On the basis of the identified miRNA and target gene pairs (Tables 1 and 2), the relationship between the miRNAs and target genes of DGBXD through which it acts on IPF was characterized (Table 5) and a putative miRNA-mRNA regulatory network involved in the action of DGBXD on IPF was developed. According to the correlations between the active compounds of DGBXD and its target genes (Table S8), further study should be performed on potential compounds in DGBXD acting on IPF through the miRNA-mRNA regulatory network.

3.9. Experimental Validation of a Bleomycin-Induced IPF Model.

To duplicate the establishment of IPF models and determine the therapeutic effects of DGBXD, HE staining was carried out to assess the pathological alterations in the various studied groups. After 21 days, extracellular matrix hyperplasia and injured alveolar structure visibly emerged, with fibroblasts appearing in the model group. On day 21, the alveolar structure was somewhat conserved in the DGBXD treatment group and the pulmonary interstitial hyperplasia was attenuated (Figure 8(a)). Additionally, the Szapiel score was significantly higher than in the control group, whereas the DGBXD treatment group was improved (Figure 8(b)). These results indicated that DGBXD could optimize the structure of the alveoli in bleomycin-induced IPF.

The extent of pulmonary fibrosis was evaluated among the groups using Masson staining. On day 21, a large number of blue-dyed collagen fibers were found in the lung interstitial fluid of the model group. Moreover, on day 21 following treatment, mild pulmonary fibrosis was observed in the DGBXD-treated group (Figure 9(a)). Additionally, the Ashcroft score was significantly higher than in the control group, whereas the DGBXD treatment group was improved (Figure 9(b)).

3.10. Validation of miRNA-mRNA Pairs in the miRNA-mRNA Regulatory Network.

We used qRT-PCR to investigate the expression level of mir-493 along with its target gene Olr1, as well as the expression level of mir-338 along with its target gene Hif1a, in lung tissues. In full agreement with the predicted results, the experimental validation demonstrated that mir-493 expression was remarkably elevated in the IPF model group, compared with that in the control group, and considerably attenuated in the DGBXD treatment group compared with that in the model group (Figure 10(a)). Moreover, the mRNA expression of Olr1 was shown to have significantly decreased in the IPF model group compared with that in the control group and to be remarkably elevated in the DGBXD treatment group compared with that in the model group (Figure 10(b)).

mir-338 expression was also significantly attenuated in the IPF model group compared with that in the control

(Figure 6(a)). The target genes for the downmodulated DE-miRNAs were found to be particularly associated with miRNAs, central carbon metabolism, transcriptional misregulation, proteoglycans in cancer, bladder cancer, leukocyte transendothelial migration, relaxin signaling pathway, fluid shear stress and atherosclerosis, signaling pathways regulating pluripotency of stem cells, and arrhythmogenic right ventricular cardiomyopathy, among others (Figure 6(b)).
group and significantly elevated in the DGBXD treatment group compared with that in the model group (Figure 10(c)). Finally, the mRNA expression of Hif1a was shown to be markedly increased in the IPF model group compared with that in the control group and substantially attenuated in the DGBXD treatment group compared with that in the model group (Figure 10(d)).

4. Discussion

IPF is an interstitial disease with UIP as its main pathological manifestation. IPF cannot currently be cured and its prognosis remains poor [49, 50]. Although many related studies have been reported, the mechanism behind the occurrence and development of IPF are still not very clear.
Thus far, studies have shown that epithelial-mesenchymal transition (EMT) and myofibroblast differentiation may be involved in the onset and progression of IPF [51–53]. Moreover, mitochondrial dysfunction and metabolic reprogramming are considered drivers of IPF [54].

Several studies explained the expression and function of miRNA have focused on the functions of miRNAs in cell proliferative ability, apoptosis, migratory function, differentiation, and energy metabolism [15–19]. MiRNAs are also closely related to EMT and myofibroblast differentiation [55–58].

Various studies have demonstrated that miRNA-mRNA regulation performs indispensable functions in the respiratory system. According to the results of an integrative investigation of miRNA-mRNA expression in nonsmall cell lung cancer, miRNAs might be a major modulatory factor regulating basic cellular activities and cell differentiation [59, 60]. Moreover, integrative analysis of miRNA-mRNA expression indicated that miRNA-mRNA expression is associated with the influenza virus [61]. Changes in the expression profiles of miRNA-mRNA in lung tissue in a mouse model also revealed the pathophysiology of bronchopulmonary dysplasia [62].

Recently, a putative IPF-related miRNA-mRNA regulatory network was established [23]. A search of the GEO database was carried out in accordance with previously reported methods, and differential expression analysis was carried out with the aid of miRNA and mRNA microarray datasets. As a result, 14 DE-miRNAs were found to be upregulated in IPF, whereas six DE-miRNAs were downregulated. The majority of DE-miRNA expression patterns were in line with those observed in earlier studies. For instance, miR-31 was reported to be considerably upregulated in the serum of IPF patients, compared with the level in healthy controls [63], and the levels of miR-31 expression were found to be positively correlated with the levels of SMAD2/3 expression in patients with IPF, while transforming growth factor-β (TGF-β) was found to induce miR-31 levels in A549 cells [64].

Expression levels of miR-410, miR-382, miR-299-5p, miR-369-5p, miR-409-3p, miR-487b, miR-127-3p, miR-493,
miR-409-5p, and miR-154 are also higher in IPF [65]. Moreover, the expression levels of miR-410 and TGF-β1 are high in lung tissue of fibrosis model rats [66]. Furthermore, the expression of miR-154 is upmodulated in the lungs of individuals experiencing pulmonary fibrosis [67]. TGF-β suppresses the level of miR-184 in A549 cells, elevates miR-184, and ameliorates the viability of A549 cells induced by TGF-β [64]. MiR-338 reduces EMT and delays the development of pulmonary fibrosis [68–70]. Meanwhile, miR-326 modulates the expression of TGF-β1 and alleviates lung fibrosis [71], and miR-326 suppresses the inflammatory response and enhances autophagy in pulmonary fibrosis induced by silica [72]. However, inconsistent results have been reported. One study found that the suppression of miR-495-3p could inhibit the S1PR3/SMAD2/SMAD3 pathway and suppress EMT [73].

After integrating DE-miRNAs and their anticipated target genes, several target genes of DE-miRNAs involved in IPF were obtained, which included 49 target genes for upmodulated DE-miRNAs and 53 target genes for downmodulated ones. Subsequently, GO functional enrichment and pathway analyses were conducted. Pathway enrichment analysis illustrated that the target genes were particularly associated with cancer-related pathways, rheumatoid arthritis, signaling pathways regulating pluripotency of stem cells, central carbon metabolism, miRNAs, transcriptional misregulation, fluid shear stress, and atherosclerosis. These functions and pathways are related to mitochondrial activity and metabolism. For instance, the gene expression programs that establish and maintain specific cell states are controlled by...

**Table 3: Active compounds in DGBXD determined by TCMSP.**

| Herb        | Active compound                                      | Compound id         | OB (%) | DL |
|-------------|------------------------------------------------------|---------------------|--------|----|
| RA          | Mairin                                               | MOL000211           | 55.38  | 0.78 |
| RA          | Jaranol                                              | MOL000239           | 50.83  | 0.29 |
| RA          | Hederagenin                                          | MOL000296           | 36.91  | 0.75 |
| RA          | (3 S, 8 S, 9 S, 10 R, 13 R, 14 S, 17 R)-10, 13-Dimethyl-17-[(2 R, 5 S)-5-propan-2-yloctan-2-yl]-2, 3, 4, 7, 8, 9, 11, 12, 14, 15, 16, 17-dodecahydro-1h-cyclopenta [a] phenanthren-3-ol | MOL000033           | 36.23  | 0.78 |
| RA          | Isorhamnetin                                         | MOL000354           | 49.60  | 0.31 |
| RA          | 3, 9-di-O-Methylhuissolin                            | MOL000371           | 53.74  | 0.48 |
| RA          | 5′-Hydroxyis-muronulatol-2′, 5′-di-O-glucoside       | MOL000374           | 41.72  | 0.69 |
| RA          | 7-O-Methylisoucronulatol                             | MOL000378           | 74.69  | 0.30 |
| RA          | 9, 10-Dimethoxyterocarpan-3-O-β-D-glucoside         | MOL000379           | 36.74  | 0.92 |
| RA          | (6aR, 11aR)-9, 10-Dimethoxy-6a, 11a-dihydro-6h-benzofuran [3, 2-c]chromen-3-ol | MOL000380           | 64.26  | 0.42 |
| RA          | Bisfendate                                           | MOL000387           | 31.10  | 0.67 |
| RA          | Formononetin                                         | MOL000392           | 69.67  | 0.21 |
| RA          | Isolavananone                                        | MOL000398           | 109.99 | 0.30 |
| RA          | Calycosin                                            | MOL000417           | 47.75  | 0.24 |
| RA          | Kaempferol                                           | MOL000422           | 41.88  | 0.24 |
| RA          | FA                                                   | MOL000433           | 68.96  | 0.71 |
| RA          | (3R)-3-(2-Hydroxy-3, 4-dimethoxyphenyl)chroman-7-ol   | MOL000438           | 67.67  | 0.26 |
| RA          | Isoucronulatol-7, 2′-di-O-glucosiole                 | MOL000439           | 49.28  | 0.62 |
| RA          | 1, 7-Dihydroxy-3, 9-dimethoxy pterocarpene           | MOL000442           | 39.05  | 0.48 |
| RA          | Quercetin                                            | MOL000098           | 46.43  | 0.28 |
| RAS         | Beta-sitosterol                                       | MOL000358           | 36.91  | 0.75 |
| RAS         | Stigmasterol                                         | MOL000449           | 43.83  | 0.76 |

DGBXD: Danggui Buxue decoction; TCMSP: Traditional Chinese Medicine Systems Pharmacology database and analysis platform; OB: oral bioavailability; DL: drug-likeness; RA: Radix Astragali; RAS: Radix Angelicae Sinensis.
by thousands of transcription factors, cofactors, and chromatin regulators, whose misregulation can cause a broad range of diseases [74]. Metabolic reprogramming in tumors is closely related to autophagy and mitophagy [75]. Intestinal microbiota metabolism is associated with atherosclerosis [76]. The role of cancer stem cell metabolism in carcinogenesis is a major focus in cancer research [77]. Mitochondrial dysfunction is associated with the initiation and

| Target genes of upregulated DE-miRNAs | Active target genes of DGBXD |
|--------------------------------------|-----------------------------|
| PGR                                 | ADRA2A                      |
| NCOA2                               | OLR1                        |
| PTGS1                               | HAS2                        |
| PTGS2                               | TOP1                        |
| HSP90AA1                            | PLAU                        |
| KCNH2                               | LTA4H                       |
| DRD1                                | MAOB                        |
| CHRMS1                              | CTRB1                       |
| SCN5A                               | ADRB1                       |
| ADRA1A                              | NOS2                        |
| PGR                                 | ADRA2A                      |
| NCOA2                               | OLR1                        |
| PTGS1                               | HAS2                        |
| PTGS2                               | TOP1                        |
| HSP90AA1                            | PLAU                        |
| KCNH2                               | LTA4H                       |
| DRD1                                | MAOB                        |
| CHRMS1                              | CTRB1                       |
| SCN5A                               | ADRB1                       |
| ADRA1A                              | NOS2                        |
| PGR                                 | ADRA2A                      |
| NCOA2                               | OLR1                        |
| PTGS1                               | HAS2                        |
| PTGS2                               | TOP1                        |
| HSP90AA1                            | PLAU                        |
| KCNH2                               | LTA4H                       |
| DRD1                                | MAOB                        |
| CHRMS1                              | CTRB1                       |
| SCN5A                               | ADRB1                       |
| ADRA1A                              | NOS2                        |
| PGR                                 | ADRA2A                      |
| NCOA2                               | OLR1                        |
| PTGS1                               | HAS2                        |
| PTGS2                               | TOP1                        |
| HSP90AA1                            | PLAU                        |
| KCNH2                               | LTA4H                       |
| DRD1                                | MAOB                        |
| CHRMS1                              | CTRB1                       |
| SCN5A                               | ADRB1                       |
| ADRA1A                              | NOS2                        |
| PGR                                 | ADRA2A                      |
| NCOA2                               | OLR1                        |
| PTGS1                               | HAS2                        |
| PTGS2                               | TOP1                        |
| HSP90AA1                            | PLAU                        |
| KCNH2                               | LTA4H                       |
| DRD1                                | MAOB                        |
| CHRMS1                              | CTRB1                       |
| SCN5A                               | ADRB1                       |
| ADRA1A                              | NOS2                        |

| Target genes of downregulated DE-miRNAs | Active target genes of DGBXD |
|-----------------------------------------|-----------------------------|
| BCL2                                   | GABRA1                      |
| BAX                                    | MAPK8                       |
| CAPS9                                  | CALM1                       |
| JUN                                    | MAPK14                      |
| CASP3                                  | HMOX1                       |
| CASP8                                  | MPK3A                       |
| PRKCA                                  | CYP3A4                      |
| PON1                                   | CYP1A1                      |
| MAP2                                   | ICAM1                       |
| NR3C2                                  | F7                          |
| ADH1C                                  | HTR                         |
| IGH1                                   | ACHET                       |
| RXRA                                   | RELA                        |
| NCOA1                                  | NCF1                        |

Figure 7: Identified target genes of DGBXD acting on IPF. (a) The overlap of the 196 active target genes of DGBXD with the 49 target genes of upregulated DE-miRNAs was determined, which identified six downregulated target genes of DGBXD acting on IPF. (b) The overlap of the 196 active target genes of DGBXD with the 53 target genes of downregulated DE-miRNAs was determined, which identified six upregulated target genes of DGBXD acting on IPF.
DGBXD, a TCM formulation, was first described by Li Dongyuan in the differentiation of endogenous and exogenous disorders (Nei Wai Shang Bian Huo Lun in Chinese) in 1247 CE. This herbal formula contains RA and RAS. DGBXD consists of the combination of herbs of 30 g of RA and 6 g of RAS [24]. According to TCM theory, DGBXD can be used for nourishing qi and enriching blood [87]. DGBXD can improve lung, spleen, and kidney deficiency, strengthen the blood circulation to remove blood stasis, and make qi flourishing stasis, in line with the pathological mechanism of IPF, which is also considered to be related to mitochondria and energy metabolism in modern medicine [88, 89].

A systematic review of RA and RAS in the treatment of IPF was previously performed, which confirmed their effectiveness and safety in IPF patients [25]. Network pharmacology studies were also carried out, clarifying the multipathway, multitarget, and multicomponent mechanism by which RA and RAS act in the treatment of IPF [26, 27]. These studies also provided a basis for in-depth study of the use of DGBXD to treat IPF.

Using a network pharmacology approach, 196 target genes of DGBXD, as well as 22 active compounds, were obtained in this study. The 196 active target genes of DGBXD were intersected with the target genes for DE-miRNAs, out of which 49 were upmodulated and 53 were downmodulated in IPF, resulting in the identification of six downmodulated and six upmodulated target genes of DGBXD that play certain roles in IPF. Some of these genes were associated with mitochondrial function and metabolism. Mitochondrial dysfunction is closely related to nuclear factor-κB and oxidized low-density-lipoprotein receptor 1 (OLR1) in atrial tissue during atrial fibrillation [90]. The association of OLR1 with angiogenesis, whereas the administration of combined with miR-410 was demonstrated to be more effective (SPARC) reduces vascular endothelial growth factor-A (VEGFA) expression in NB1691 neuroblastoma cells via miR-410; in addition, the overexpression of SPARC combined with miR-410 was demonstrated to be more effective at alleviating angiogenesis, whereas the administration of miR-410 blockers attenuated the suppression of VEGFA mediated by SPARC in NB1691 cells [94]. A DNA methyltransferase inhibitor, 5-AzaC, has also been shown to increase miR-495 expression, while decreasing the

| Target genes | Corresponding miRNA |
|--------------|---------------------|
| PKIA         | miR-654-3p          |
| FOS          | miR-493-5p          |
| ADRB1        | miR-654-3p          |
| VEGFA        | miR-410-3p          |
| MAP2         | miR-493-3p          |
| OLR1         | miR-493-5p          |
| MMP2         | miR-338-3p          |
| TOP2A        | miR-203a-3p         |
| HIF1A        | miR-338-3p          |
| MMP1         | miR-203a-3p         |
| TP63         | miR-203a-3p         |
| MMP9         | miR-338-3p          |

DGBXD: Danggui Buxue decoction; IPF: idiopathic pulmonary fibrosis; mRNA: microRNA.
expression of its target gene signal transducer and activator of transcription 3 (STAT3), as well as the expression of its downstream target VEGF. These anticancer characteristics of 5-AzaC have also been confirmed in breast cancer cells [95]. In the initiation and progression of nasopharyngeal carcinoma, miR-338-3p inhibits migratory and proliferative abilities by targeting HIF1A directly, which could represent a novel therapeutic target [96]. These studies may have

---

**Figure 8**: HE staining of lung samples. (a) On day 21, extracellular matrix proliferation and injured alveolar structure emerged visibly (black arrow), while fibroblasts (green arrow) appeared in the model group. The DGBXD treatment group exhibited slight preservation of alveolar structure and suppression of pulmonary interstitial hyperplasia on day 21. (b) Assessment by the Szapiel score. The Szapiel score was significantly higher than in the control group, whereas the DGBXD treatment group was improved.

**Figure 9**: Masson staining of lung samples. (a) On day 21, a large number of blue-dyed collagen fibers were observed in the interstitial lung fluid of the model group. On day 21, mild lung fibrosis was observed in the DGBXD treatment groups. (b) Assessment by the Ashcroft score. The Ashcroft score was significantly higher than in the control group, whereas the DGBXD treatment group was improved.
identified the potential targets for treating related diseases. In particular, the miRNA-mRNA regulatory network of DGBXD acting on IPF warrants further research, with the aim of verifying the related potential mechanism. Offi_he majority of the miRNA-mRNA pairs included in the network established in this study and possibly leading to the pathophysiology of IPF have not previously been explored, so studies of them are required to investigate and discover novel disease processes and treatment targets.

On the basis of previous animal model studies of the action of DGBXD on IPF, the dosage of DGBXD used and the effect of DGBXD in bleomycin-induced IPF animal model are corroborative [97–101]. Then, a bleomycin-induced IPF mouse model was duplicated, and the dosage of DGBXD intragastrically administered was calculated according to a body weight of 70 kg for adults using 30 g of RA and 6 g of RAS. Finally, the results of HE staining and Masson staining of lung sections confirmed the therapeutic effects of DGBXD. These results are consistent with previous animal model studies on IPF, and DGBXD clearly has an effect in bleomycin-induced IPF mice, which provides a basis for further mechanistic research.

After we replicated the IPF model for treatment with DGBXD, we primarily performed qRT-PCR validation of the abovementioned miRNA-mRNA pairs. Not unnaturally, genes associated with mitochondrial function and metabolism could be investigated for the first time. Offi_he expression level of mir-493 along with its target gene Olr1 and the expression level of miR-338 along with its target gene Hif1a were explored in lung tissues by qRT-PCR. mir-493 expression was substantially upmodulated in IPF groups, whereas the gene Olr1 was downregulated, and mir-338 expression was substantially downmodulated in the IPF group along with the upregulation of Hif1a. In addition, mir-493 expression was remarkably attenuated in the DGBXD groups along with an increase in Olr1, whereas mir-

---

**Figure 10:** Validation of miRNA-mRNA pairs using qRT-PCR. (a) Substantial elevation in mir-493 expression level was observed in the model group in contrast with that in the control group. Nevertheless, considerable attenuation in mir-493 expression was observed in the treatment group compared with that in the model group. (b) The mRNA expression of Olr1 was dramatically attenuated in the model group in comparison with that in the control group, whereas it was substantially elevated in the treatment group compared with that in the model group, with a statistically significant difference. (c) mir-338 expression was shown to undergo significant attenuation in the model group compared with that in the control group, while being substantially elevated in the treatment group compared with that in the model group. (d) The Hif1a mRNA expression was found to be substantially elevated in the model group compared with that in the control group, while being substantially reduced in the treatment group compared with that in the model group.
338 expression was considerably elevated in the DGBXD groups along with a decrease in Hif1a. These validation results are consistent with the regulatory network that we established, which is very important and meaningful. These miRNA-mRNA pairs associated with mitochondrial dysfunction and metabolic reprogramming could thus be prioritized for further investigation in basic research. According to the active compounds previously obtained, an HIF1A-associated compound is quercetin, and an OLR1-associated compound is isorhamnetin, which can provide a reference regarding the mechanism by which DGBXD acts on IPF through the miRNA-mRNA regulatory network.

Although a putative miRNA-mRNA regulatory network of DGBXD acting on IPF has been developed in this study, this work had several limitations. First, the IPF-related miRNA and mRNA microarray datasets used were mainly from the GEO database, whereas the other databases have less-relevant datasets. The number and sample size of the microarray datasets included in this study may thus have been insufficient, although we collected miRNA and mRNA microarray datasets as comprehensively as possible from the GEO database. Nonetheless, each dataset contains raw data from relevant clinical studies and a single dataset can display all of the obtained miRNA- or mRNA-related information, and these microarray datasets are also complete and reliable. Second, employing TCMSP, we successfully identified the active chemicals as well as the target genes in RA and RAS. However, the data collection method was not exhaustive and the criteria for screening for active chemicals could potentially have led to bias, but TCMSP is currently the most-extensive accessible database and most of the common active chemicals and target genes in RA and RAS in the network database can be identified in TCMSP. In fact, part of the active chemicals and target genes in RA and RAS may be missed including some active chemicals through quality control index of RA and RAS in Chinese Pharmacopoeia. Therefore, although we established the potential miRNA-mRNA regulatory network through the network database, some of the miRNA-mRNA pairs may have been missed for the above reasons. However, our purpose in this study was to find potential miRNA-mRNA pairs involved in DGBXD acting on IPF from the predictions and then perform validation. Overall, the established miRNA-mRNA regulatory network of DGBXD acting on IPF in this study is still reliable and significant, especially the experimentally validated miRNA-mRNA pairs. Finally, because we further validated the gene expression and miRNA-mRNA pairs in the regulatory network using an IPF mouse model, the validated miRNA-mRNA pairs for specific deep mechanisms require further investigation. In addition, further clinical research is required to validate the regulatory network, as well as its relationships to clinical efficacy and prognosis.

5. Conclusion

This study revealed a potential mechanism of involvement of miRNA-mRNA modulatory axes in the pathogenic mechanisms of IPF. It also developed a putative IPF-related miRNA-mRNA regulatory network through which DGBXD ameliorates IPF. Finally, relevant miRNA-mRNA pairs were experimentally verified to facilitate further research, and potential compounds in DGBXD acting on IPF through the miRNA-mRNA regulatory network can now also be further studied.

Data Availability

Data can be obtained from the corresponding author upon written request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

HZ Zhang, Xue Wang, and YC Shi contributed equally to this work. HZ Zhang, WL Jiang, and YF Zhang conceived and designed the study and wrote the manuscript. HZ Zhang, QQ Xia, WL Jiang, and YF Zhang were responsible for data collection and performed the data analysis. HZ Zhang, Xue Wang, YC Shi, MY Liu, and YF Zhang performed the experiments. WL Jiang and YF Zhang performed supervision and project administration. HZ Zhang, Xue Wang, YC Shi, MY Liu, and YF Zhang revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors thank Liwen Bianji (Edanz) (www.liwenbianji.cn) for editing the language of a draft of this manuscript. The authors express their gratitude to the researchers who previously shared microarray datasets, as well as to the producers of the web resource platforms and data processing software used in this research. This work was supported by Research Grants of Jiangyin Hospital of Traditional Chinese Medicine (202013 to WL Jiang, 202014 to YF Zhang) and Grants from the Wuxi Health Commission’s Scientific Research Project (M202154 to YF Zhang, T202130 to WL Jiang).

Supplementary Materials

Table S1: DGBXD granules. Table S2: Szapiel score system. Table S3: Ashcroft score system. Table S4: predicted target genes of upregulated DE-miRNAs (n = 1285). Table S5: predicted target genes of downregulated DE-miRNAs (n = 1411). Table S6: upregulated DE-miRNAs (n = 1160). Table S7: downregulated DE-mRNAs (n = 1427). Table S8: corresponding gene symbols of RA and RAS. (Supplementary Materials)

References

[1] G. Ragh, M. Remy-Jardin, J. L. Myers et al., “Diagnosis of idiopathic pulmonary fibrosis An official ATS/ERS/JRS/ALAT clinical practice guideline,” American Journal of Respiratory and Critical Care Medicine, vol. 198, no. 5, pp. e44–e68, 2018.
Evidence-Based Complementary and Alternative Medicine

[2] G. Shen, P. Chen, Y. Wei et al., "Viral infection increases the risk of idiopathic pulmonary fibrosis," Chest, vol. 157, no. 5, pp. 1175–1187, 2020.

[3] V. Navaratnam, K. M. Fleming, J. West et al., "The rising incidence of idiopathic pulmonary fibrosis in the UK," Thorax, vol. 66, no. 6, pp. 462–467, 2011.

[4] J. Hutchinson, A. Fogarty, R. Hubbard, and T. McKeever, "Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review," European Respiratory Journal, vol. 46, no. 3, pp. 795–806, 2015.

[5] H. Huang, X. Peng, and C. Zhong, "Idiopathic pulmonary fibrosis: the current status of its epidemiology, diagnosis, and treatment in China," Intractable and Rare Diseases Research, vol. 2, no. 3, pp. 88–93, 2013.

[6] S. Cerri, M. Monari, A. Guerrieri et al., "Real-life comparison of pirenidone and nintedanib in patients with idiopathic pulmonary fibrosis: a 24-month assessment," Respiratory Medicine, vol. 159, Article ID 105803, 2019.

[7] C. Aravena, G. Labarca, C. Venegas, A. Arenas, and G. Rada, "Pirenidone for idiopathic pulmonary fibrosis: a systematic review and meta-analysis," PLoS One, vol. 10, no. 8, Article ID e0136160, 2015.

[8] C. J. Ryerson, M. Kolb, L. Richeldi et al., "Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage," ERI Open Research, vol. 5, no. 2, 2019.

[9] Q. Wu, Y. Zhou, F.-c. Feng, and X.-m. Zhou, "Effectiveness and safety of Chinese medicine for idiopathic pulmonary fibrosis: a systematic review and meta-analysis," Chinese Journal of Integrative Medicine, vol. 25, no. 10, pp. 778–784, 2019.

[10] K. Ji, J. Ma, L. Wang, N. Li, S. Dong, and L. Shi, "Efficacy and safety of traditional Chinese medicine in idiopathic pulmonary fibrosis: a meta-analysis," Evidence-based Complementary and Alternative Medicine, vol. 2020, Article ID 1752387, 11 pages, 2020.

[11] H. J. Kim, D. Perlman, and R. Tomic, "Natural history of idiopathic pulmonary fibrosis," Respiratory Medicine, vol. 109, no. 6, pp. 661–670, 2015.

[12] M. Baker, "MicroRNAs as biomarkers," Nature, vol. 464, 2010.

[13] D. P. Bartel, "Metazoan MicroRNAs," Cell, vol. 173, no. 1, pp. 20–51, 2018.

[14] M. S. Ebert and P. A. Sharp, "Roles for microRNAs in conferring robustness to biological processes," Cell, vol. 149, no. 3, pp. 515–524, 2012.

[15] Q. Fu, Z. Lu, X. Fu, S. Ma, and X. Lu, "MicroRNA 27b promotes cardiac fibrosis by targeting the FBW7/Snail pathway," Aging, vol. 11, no. 24, pp. 11865–11879, 2019.

[16] H. Tu, D. Chen, C. Cai et al., "microRNA-143-3p attenuated development of hepatic fibrosis in autoimmune hepatitis through regulation of TAK1 phosphorylation," Journal of Cellular and Molecular Medicine, vol. 24, no. 2, pp. 1256–1267, 2020.

[17] N. Kuse, K. Kamio, A. Azuma et al., "Exosome-derived microRNA-22 ameliorates pulmonary fibrosis by regulating fibroblast-to-myofibroblast differentiation in vitro and in vivo," Journal of Nippon Medical School, vol. 87, no. 3, pp. 118–128, 2020.

[18] W. J. Dai, J. Qiu, J. Sun et al., "Downregulation of microRNA-9 reduces inflammatory response and fibroblast proliferation in mice with idiopathic pulmonary fibrosis through the ANO1-mediated TGF-β-Smad3 pathway," Journal of Cellular Physiology, vol. 234, no. 3, pp. 2552–2565, 2019.

[19] H. Bahudhanapati, J. Tan, J. A. Dutta et al., "MicroRNA-144-3p targets relaxin/insulin-like family peptide receptor 1 (RXFP1) expression in lung fibroblasts from patients with idiopathic pulmonary fibrosis," Journal of Biological Chemistry, vol. 294, no. 13, pp. 5008–5022, 2019.

[20] T. Wang, N. Wang, R. Zhang et al., "nie-du-hua-yu granules promote liver regeneration in rat models of acute liver failure: miRNA-mRNA expression analysis," Evidence-based Complementary and Alternative Medicine, vol. 2020, pp. 1–11, 2020.
Evidence-Based Complementary and Alternative Medicine

analysis,” Nucleic Acids Research, vol. 44, no. W1, pp. W135–W141, 2016.

[33] Y. Fan, M. Habib, and J. Xia, “Xeno-miRNet: a comprehensive database and analytics platform to explore xeno-miRNAs and their potential targets,” PeerJ, vol. 6, Article ID e6550, 2018.

[34] Y. Fan and J. Xia, “miRNet-functional analysis and visual exploration of miRNA-target interactions in a network context,” Methods in Molecular Biology, vol. 1819, pp. 215–233, 2018.

[35] M. E. Ritchie, B. Phipson, D. Wu et al., “Limma powers differential expression analyses for RNA-sequencing and microarray studies,” Nucleic Acids Research, vol. 43, no. 7, p. e47, 2015.

[36] E. Y. Chen, C. M. Tan, Y. Kou et al., “Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool,” BMC Bioinformatics, vol. 14, no. 1, p. 128, 2013.

[37] M. V. Kuleshov, M. R. Jones, A. D. Rouillard et al., “Enrichr: a comprehensive gene set enrichment analysis web server 2016 update,” Nucleic Acids Research, vol. 44, no. W1, pp. W90–W97, 2016.

[38] J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” Journal of Cheminformatics, vol. 6, no. 1, p. 13, 2014.

[39] Q. Xia, M. Liu, H. Li, L. Tian, J. Qi, and Y. Zhang, “Network pharmacology strategy to investigate the pharmacological mechanism of HuangQXin decoction on cough variant asthma and evidence-based medicine approach validation,” Evidence-Based Complementary and Alternative Medicine, vol. 2020, Article ID 3829092, 15 pages, 2020.

[40] T. UniProt Consortium, “UniProt: the universal protein knowledgebase,” Nucleic Acids Research, vol. 46, no. 5, p. 2699, 2018.

[41] W. Jiang, Y. Zhang, M. Liu et al., “A network pharmacology approach to explore the mechanism of Kangguan decoction in the treatment of coronavirus disease 2019 with preliminary verification,” TMR Integrative Medicine, vol. 5, Article ID e21025, 2021.

[42] P. Gu, D. Wang, J. Zhang et al., “Protective function of interleukin-22 in pulmonary fibrosis,” Clinical and Translational Medicine, vol. 11, no. 8, p. e509, 2021.

[43] T. T. X. Dong, K. J. Zhao, Q. T. Gao et al., “Chemical and biological assessment of a Chinese herbal decoction containing Radix Astragali and Radix Angelicae Sinensis: determination of drug ratio in having optimized properties,” Journal of Agricultural and Food Chemistry, vol. 54, no. 7, pp. 2767–2774, 2006.

[44] L.-P. Zhou, K.-Y. Wong, H.-T. Yeung et al., “Bone protective effects of Danshui Buxue tang alone and in combination with tamoxifen or raloxifene in vivo and in vitro,” Frontiers in Pharmacology, vol. 9, p. 779, 2018.

[45] S. Y. Xu, R. L. Bian, and X. Chen, Experimental Methodology of Pharmacology, People’s Medical Publishing House, Beijing, China, 2002.

[46] S. V. Szapiel, N. A. Elson, J. D. Fulmer, G. W. Hunninghake, and R. G. Crystal, “Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse,” American Review of Respiratory Disease, vol. 120, no. 4, pp. 893–899, 1979.

[47] T. Ashcroft, J. M. Simpson, and V. Timbrell, “Simple method of estimating severity of pulmonary fibrosis on a numerical scale,” Journal of Clinical Pathology, vol. 41, no. 4, pp. 467–470, 1988.

[48] Y. Zhang, W. Jiang, Q. Xia et al., “Construction of a potential microRNA and messenger RNA regulatory network of acute lung injury in mice,” Scientific Reports, vol. 12, no. 1, p. 777, 2022.

[49] J. Behr, A. Günther, F. Bonella et al., “German guideline for idiopathic pulmonary fibrosis—update on pharmacological therapies 2017,” Pneumologie, vol. 72, no. 02, pp. 155–168, 2018.

[50] C. C. Thomson, A. Duggal, T. Bice, D. J. Lederer, K. C. Wilson, and G. Raghu, “2018 clinical practice guideline summary for practicing clinicians: diagnosis of idiopathic pulmonary fibrosis,” Annals of The American Thoracic Society, vol. 16, no. 3, pp. 285–290, 2019.

[51] Y. Sakuma, “Epithelial-to-mesenchymal transition and its role inEGFR-mutant lung adenocarcinoma and idiopathic pulmonary fibrosis,” Pathology International, vol. 67, no. 8, pp. 379–388, 2017.

[52] F. Salton, M. Volpe, and M. Confalonieri, “Epithelial-mesenchymal transition in the pathogenesis of idiopathic pulmonary fibrosis,” Medicina, vol. 55, no. 4, p. 83, 2019.

[53] J. A. Gibb, M. P. Lazaropoulos, and J. W. Elrod, “Myofibroblasts and fibrosis,” Circulation Research, vol. 127, no. 3, pp. 427–440, 2020.

[54] M. Bueno, J. Calyeca, M. Rojas, and A. L. Mora, “Mitochondria dysfunction and metabolic reprogramming as drivers of idiopathic pulmonary fibrosis,” Redox Biology, vol. 33, Article ID 101509, 2020.

[55] S. P. Kabekkodu, D. Adiga, P. V. Jishnu, V. K. Varghese, K. Satyamoorthy, and S. P. Kabekkodu, “Role of miRNA clusters in epithelial to mesenchymal transition in cancer,” Frontiers in Bioscience, vol. 12, no. 1, pp. 48–78, 2020.

[56] Z. Liu, X. Liang, X. Li et al., “MiRNA-21 functions in ionizing radiation-induced epithelium-to-mesenchymal transition (EMT) by downregulating PTEN,” Toxicology Research, vol. 8, no. 3, pp. 328–340, 2019.

[57] C. Wang, H. Cao, S. Gu, C. Shi, X. Chen, and X. Han, “Expression analysis of microRNAs and mRNAs in myofibroblast differentiation of lung resident mesenchymal stem cells,” Differentiation, vol. 112, pp. 10–16, 2020.

[58] P. Wei, Y. Xie, P. W. Abel et al., “Transforming growth factor (TGF)-β1-induced miR-133a inhibits myofibroblast differentiation and pulmonary fibrosis,” Cell Death and Disease, vol. 10, no. 9, p. 670, 2019.

[59] R. Ma, C. Wang, J. Wang, D. Wang, and J. Xu, “miRNA-mRNA interaction network in non-small cell lung cancer,” Interdisciplinary Sciences: Computational Life Sciences, vol. 8, no. 3, pp. 209–219, 2016.

[60] A. Najafi, M. Tavallaei, and S. M. Hosseini, “A systems biology approach for miRNA-mRNA expression patterns analysis in non-small cell lung cancer,” Cancer Biomarkers, vol. 16, no. 1, pp. 31–45, 2016.

[61] L. Gao, J. Gao, Y. Liang et al., “Integration analysis of a miRNA-mRNA expression in A549 cells infected with a novel H3N2 swine influenza virus and the 2009 H1N1 pandemic influenza virus,” Infection, Genetics and Evolution, vol. 74, Article ID 103922, 2019.

[62] J. Wang, J. Yin, X. Wang et al., “Changing expression profiles of miRNA, lncRNA, circRNA, and mRNA in lung tissue reveal the pathophysiological of bronchopulmonary dysplasia (BPD) in mouse model,” Journal of Cellular and Molecular Medicine, vol. 22, no. 6, pp. 2430–2439, 2018.

[63] J. Wang, Y. Wang, W. Wang, J. Wang, J. Wang, and Z. Xu, “Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression,” Gene, vol. 562, no. 1, pp. 138–144, 2015.
[64] C.-J. Wang, B.-B. Li, Y.-J. Tan, G.-M. Zhang, G.-L. Cheng, and Y.-S. Ren, “MicroRNA-31/184 is involved in transforming growth factor-β-induced apoptosis in A549 human alveolar adenocarcinoma cells,” Life Sciences, vol. 242, Article ID 117205, 2020.

[65] J. Milosevic, K. Pandit, M. Magister et al., “Profibrotic role of miR-154 in pulmonary fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 47, no. 6, pp. 879–887, 2012.

[66] H. Liu, Y. He, Z. Jiang, S. Shen, J. Mei, and M. Tang, “Prodigiosin alleviates pulmonary fibrosis through inhibiting miRNA-410 and TGF-β1/ADAMTS-1 signaling pathway,” Cellular Physiology and Biochemistry, vol. 49, no. 2, pp. 501–511, 2018.

[67] B. C. Bernardo, S. S. Nguyen, X.-M. Gao et al., “Inhibition of miR-154 protects against cardiac dysfunction and fibrosis in a mouse model of pressure overload,” Scientific Reports, vol. 6, no. 1, Article ID 22442, 2016.

[68] H. Zhang, X. Liu, S. Chen et al., “Tectorigenin inhibits the in vitro proliferation and enhances miR-338 expression of pulmonary fibroblasts in rats with idiopathic pulmonary fibrosis,” Journal of Ethnopharmacology, vol. 131, no. 1, pp. 165–173, 2010.

[69] Y. Zhuang, J. Dai, Y. Wang et al., “MiR-338 targeting smoothened to inhibit pulmonary fibrosis by epithelial-mesenchymal transition,” American Journal of Tourism Research, vol. 8, no. 7, pp. 3206–3213, 2016.

[70] Y. Zhuang, J. Dai, Y. Wang et al., “MiR-338 suppresses fibrotic pathogenesis in pulmonary fibrosis through targeting LPA1,” American Journal of Tourism Research, vol. 8, no. 7, pp. 3197–3205, 2016.

[71] S. Das, M. Kumar, V. Negi et al., “MicroRNA-326 regulates profibrotic functions of transforming growth factor-β in pulmonary fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 50, no. 5, pp. 882–892, 2014.

[72] T. Xu, W. Yan, Q. Wu et al., “MiR-326 inhibits inflammation and promotes autophagy in silica-induced pulmonary fibrosis through targeting TNFSF14 and PTBP1,” Chemical Research in Toxicology, vol. 32, no. 11, pp. 2192–2203, 2019.

[73] L. Gong, X. Wu, X. Li et al., “SIPR3 deficiency alleviates radiation-induced pulmonary fibrosis through the regulation of epithelial-mesenchymal transition by targeting miR-495-3p,” Journal of Cellular Physiology, vol. 235, no. 3, pp. 2310–2320, 2020.

[74] T. I. Lee and R. A. Young, “Transcriptional regulation and its misregulation in disease,” Cell, vol. 152, no. 6, pp. 1237–1251, 2013.

[75] F. Ferro, S. Servais, P. Besson, S. Roger, J.-F. Dumas, and L. Brisson, “Autophagy and mitophagy in cancer metabolic remodelling,” Seminars in Cell and Developmental Biology, vol. 98, pp. 129–138, 2020.

[76] T.-X. Liu, H.-T. Niu, and S.-Y. Zhang, “Intestinal microbiota metabolism and atherosclerosis,” Chinese Medical Journal, vol. 128, no. 20, pp. 2805–2811, 2015.

[77] M. Peiris-Pagès, U. E. Martínez-Outschoorn, R. G. Pestell, F. Sotgia, and M. P. Lisanti, “Cancer stem cell metabolism,” Breast Cancer Research, vol. 18, no. 1, p. 55, 2016.

[78] W. Peng, G. Cai, Y. Xia et al., “Mitochondrial dysfunction in atherosclerosis,” DNA and Cell Biology, vol. 38, no. 7, pp. 597–606, 2019.

[79] F. V. Duarte, C. M. Palmeira, and A. P. Rolo, “The emerging role of MitomiRs in the pathophysiology of human disease,” Advances in Experimental Medicine and Biology, vol. 888, pp. 123–154, 2015.

[80] X. Wang, Z. Chen, X. Fan et al., “Inhibition of DNM1L and mitochondrial fission attenuates inflammatory response in fibroblast-like synoviocytes of rheumatoid arthritis,” Journal of Cellular and Molecular Medicine, vol. 24, no. 2, pp. 1516–1528, 2020.

[81] H. Chen and D. C. Chan, “Mitochondrial dynamics in regulating the unique phenotypes of cancer and stem cells,” Cell Metabolism, vol. 26, no. 1, pp. 39–48, 2017.

[82] S. Sripradavan, M. Guha, A. Kashina, and N. G. Avadhani, “Mitochondrial dysfunction and mitochondrial dynamics: The cancer connection,” Biochimica et Biophysica Acta (BBA)—Bioenergetics, vol. 1858, no. 8, pp. 602–614, 2017.

[83] X. Li, J. Liu, L. Lin et al., “Traditional Chinese medicine shuang ning xin attenuates myocardial ischemia/reperfusion injury by preserving of mitochondrial function,” Evidence-based Complementary and Alternative Medicine, vol. 2014, pp. 1–10, 2014.

[84] L. Zhu, Z. Chen, K. Han et al., “Correlation between mitochondrial dysfunction, cardiovascular diseases, and traditional Chinese medicine,” Evidence-based Complementary and Alternative Medicine, vol. 2020, pp. 1–11, 2020.

[85] M. Yang and L. Lao, “Emerging applications of metabolomics in traditional Chinese medicine treating hypertension: biomarkers, pathways and more,” Frontiers in Pharmacology, vol. 10, p. 158, 2019.

[86] S. Wang, J.-L. Fu, H.-F. Hao, Y.-N. Jiao, P.-P. Li, and S.-Y. Han, “Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy,” Pharmacological Research, vol. 170, Article ID 105728, 2021.

[87] A. G. Gong, L. M. Zhang, C. T. Lam et al., “Polysaccharide of Denggui Buxue tang, an ancient Chinese herbal decoction, induces expression of pro-inflammatory cytokines possibly via activation of NFκB signaling in cultured RAW 264.7 cells,” Phytotherapy Research, vol. 31, no. 2, pp. 274–283, 2017.

[88] K. K. L. Kwan, Y. Huang, K. W. Leung, T. T. X. Dong, and K. W. K. Tsim, “Danggui Buxue tang, a Chinese herbal decoction containing Astragalus Radix and Angelicae sinensis radix, modulates mitochondrial bioenergetics in cultured cardiomyoblasts,” Frontiers in Pharmacology, vol. 10, p. 614, 2019.

[89] A. Gong, K. Lau, L. Zhang, H. Lin, T. Dong, and K. Tsim, “Danggui Buxue tang, Chinese herbal decoction containing Astragalus Radix and Angelicae sinensis radix, induces production of nitric oxide in endothelial cells: signaling mediated by phosphorylation of endothelial nitric oxide synthase,” Planta Medica, vol. 82, no. 5, pp. 418–423, 2016.

[90] A. Bukowska, L. Schild, G. Keilhoff et al., “Mitochondrial dysfunction and redox signaling in atrial tachyarhythmia,” Experimental Biology and Medicine, vol. 233, no. 5, pp. 558–574, 2008.

[91] Y. Uchikado, Y. Ikeda, Y. Sasaki, M. Iwabayashi, Y. Akasaki, and M. Ohishi, “Association of lectin-like oxidized low-density lipoprotein receptor-1 with angiotensin II type 1 receptor impacts mitochondrial quality control, offering promise for the treatment of vascular senescence,” Frontiers in Cardiovascular Medicine, vol. 8, Article ID 788655, 2021.

[92] C.-C. Hsu, C.-H. Wang, L.-C. Wu et al., “Mitochondrial misregulation in disease,” biomarkers, pathways and more,” Frontiers in Pharmacology, vol. 10, p. 158, 2019.
A. Garedew and S. Moncada, “Mitochondrial dysfunction and HIF1α stabilization in inflammation,” Journal of Cell Science, vol. 121, no. 20, pp. 3468–3475, 2008.

J. Boyineni, S. Tanpure, M. Gnanamony et al., “SPARC overexpression combined with radiation retards angiogenesis by suppressing VEGF-A via miR-410 in human neuroblastoma cells,” International Journal of Oncology, vol. 49, no. 4, pp. 1394–1406, 2016.

Y. Chen, D. Luo, W. Tian, Z. Li, and X. Zhang, “Demethylation of miR-495 inhibits cell proliferation, migration and promotes apoptosis by targeting STAT-3 in breast cancer,” Oncology Reports, vol. 37, no. 6, pp. 3581–3589, 2017.

Y. Shan, X. Li, B. You, S. Shi, Q. Zhang, and Y. You, “MicroRNA-338 inhibits migration and proliferation by targeting hypoxia-induced factor 1α in nasopharyngeal carcinoma,” Oncology Reports, vol. 34, no. 4, pp. 1943–1952, 2015.

C. Zhao, H. Li, X. Liu et al., “Dissecting the underlying pharmaceutical mechanism of Danggui Buxue decoction acting on idiopathic pulmonary fibrosis with network pharmacology,” Traditional Medicine Research, vol. 5, no. 4, 2020.

J. Wang, H. Wang, F. Fang et al., “Danggui Buxue tang ameliorates bleomycin-induced pulmonary fibrosis by suppressing the TLR4/NLRP3 signaling pathway in rats,” Evidence-based Complementary and Alternative Medicine, vol. 2021, pp. 1–13, 2021.

J. Wang, C. Fang, S. Wang et al., “Danggui Buxue Tang ameliorates bleomycin-induced pulmonary fibrosis in rats through inhibiting transforming growth factor-beta1/Smad3/plasminogen activator inhibitor-1 signaling pathway,” Journal of Traditional Chinese Medicine, vol. 40, no. 2, pp. 236–244, 2020.

J. Gao, L.-j. Feng, Y. Huang et al., “Total glucosides of Danggui Buxue Tang attenuates bleomycin-induced pulmonary fibrosis via inhibition of extracellular matrix remodelling,” Journal of Pharmacy and Pharmacology, vol. 64, no. 6, pp. 811–820, 2012.

P. Zhao, W.-C. Zhou, D.-L. Li et al., “Total glucosides of Danggui Buxue tang attenuate BLM-induced pulmonary fibrosis via regulating oxidative stress by inhibiting NOX4,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 645814, 10 pages, 2015.